{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Palandri F"],"funding":["Ministero della Salute"],"pagination":["e70062"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12369922"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["131(17)"],"pubmed_abstract":["<h4>Background</h4>The response to ruxolitinib after 6 months (RR6) model allows early identification of ruxolitinib-treated myelofibrosis (MF) patients with poorer overall survival (OS); however, it is less applicable to lower-risk patients.<h4>Methods</h4>To further explore this, the authors performed a subanalysis of the \"RUX-MF\" study (NCT06516406) with an aim to validate the RR6 and to develop a score specific for intermediate-1 DIPSS/MYSEC-PM risk patients.<h4>Results</h4>Among the 776 evaluable patients, 34.4%, 47.8%, and 17.8% were at low, intermediate, and high RR6 risk, with 5-year OS of 64.1%, 51.8%, and 44.5%, respectively (p < .001). In the 428 intermediate-1 patients, the RR6 model did not discriminate between intermediate and low-risk patients (5-year OS: 74.4% vs. 72.0%, p "],"journal":["Cancer"],"pubmed_title":["Revised \"iRR6\" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib."],"pmcid":["PMC12369922"],"funding_grant_id":["RC-2024-2790083"],"pubmed_authors":["Pugliese N","Bonifacio M","Crugnola M","Scalzulli E","Strazimiri A","Cilloni D","Duminuco A","Heidel FH","Benevolo G","Martino B","Isidori A","Breccia M","Palandri F","Beggiato E","Branzanti F","Lemoli RM","Dedola A","Morsia E","Tosoni L","Binotto G","Tieghi A","Farina M","Pane F","Abruzzese E","Caocci G","Kuykendall AT","Bocchia M","Sartor C","Palumbo GA","Cavazzini F","Tiribelli M","Elli EM"],"additional_accession":[]},"is_claimable":false,"name":"Revised \"iRR6\" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.","description":"<h4>Background</h4>The response to ruxolitinib after 6 months (RR6) model allows early identification of ruxolitinib-treated myelofibrosis (MF) patients with poorer overall survival (OS); however, it is less applicable to lower-risk patients.<h4>Methods</h4>To further explore this, the authors performed a subanalysis of the \"RUX-MF\" study (NCT06516406) with an aim to validate the RR6 and to develop a score specific for intermediate-1 DIPSS/MYSEC-PM risk patients.<h4>Results</h4>Among the 776 evaluable patients, 34.4%, 47.8%, and 17.8% were at low, intermediate, and high RR6 risk, with 5-year OS of 64.1%, 51.8%, and 44.5%, respectively (p < .001). In the 428 intermediate-1 patients, the RR6 model did not discriminate between intermediate and low-risk patients (5-year OS: 74.4% vs. 72.0%, p ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-15T06:26:49.875Z","creation":"2026-07-01T03:07:16.517Z"},"accession":"S-EPMC12369922","cross_references":{"pubmed":["40839414"],"doi":["10.1002/cncr.70062"]}}